Microbot Medical (NASDAQ:MBOT) Issues Earnings Results, Beats Expectations By $0.03 EPS

Posted by Brenda Bartman on May 14th, 2026

Microbot Medical (NASDAQ:MBOT – Get Free Report) issued its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03, FiscalAI reports. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.30 million.

Microbot Medical Stock Up 1.0%

Shares of MBOT opened at $1.93 on Tuesday. Microbot Medical has a 52 week low of $1.60 and a 52 week high of $4.67. The company has a market capitalization of $129.64 million, a price-to-earnings ratio of -7.42 and a beta of 1.04. The stock’s 50-day moving average price is $1.92 and its 200-day moving average price is $2.12. The company has a quick ratio of 21.93, a current ratio of 22.59 and a debt-to-equity ratio of 0.01.

Wall Street Analysts Forecast Growth

MBOT has been the topic of several recent analyst reports. Wall Street Zen raised shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Microbot Medical in a report on Friday, April 10th. Loop Capital set a $4.00 price target on shares of Microbot Medical in a research report on Wednesday, June 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Microbot Medical in a research report on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $6.62.

Check Out Our Latest Stock Report on MBOT

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in Microbot Medical in the 4th quarter worth about $63,000. Cetera Investment Advisers boosted its stake in Microbot Medical by 38.8% during the 4th quarter. Cetera Investment Advisers now owns 29,313 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 8,201 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Microbot Medical during the 4th quarter valued at about $49,000. Goldman Sachs Group Inc. purchased a new stake in shares of Microbot Medical in the fourth quarter valued at approximately $69,000. Finally, Wexford Capital LP purchased a new stake in Microbot Medical in the 3rd quarter valued at $50,000. Institutional investors and hedge funds own 16.30% of the company’s stock.

About Microbot Medical

(Get Free Report)

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.